Autosomal dominant spastic paraplegia type 6

Autosomal dominant spastic paraplegia type 6 (SPG6) is a rare hereditary spastic paraplegia caused by mutations in the NIPA1 gene (also known as SPG6 gene) located on chromosome 15q11.2. Hereditary spastic paraplegias are a group of neurodegenerative disorders characterized by progressive weakness and spasticity (stiffness) of the lower limbs due to degeneration of the corticospinal tract motor neurons. SPG6 is classified as a "pure" or "uncomplicated" form of hereditary spastic paraplegia, meaning that the primary symptoms are largely confined to progressive lower extremity spasticity and weakness, with associated hyperreflexia (overactive reflexes), extensor plantar responses (Babinski sign), and gait difficulties. The onset of SPG6 is variable but typically occurs in adolescence or adulthood, though childhood onset has been reported. Patients usually first notice stiffness or difficulty walking, which gradually worsens over time. Urinary urgency or bladder dysfunction may also develop. Sensory function is generally preserved, and upper limb involvement is usually minimal or absent. The rate of disease progression varies considerably, even among members of the same family. There is currently no cure or disease-modifying treatment for SPG6. Management is symptomatic and supportive, focusing on maintaining mobility and quality of life. This includes physical therapy to preserve muscle strength and flexibility, antispasticity medications such as baclofen or tizanidine, and assistive devices (canes, walkers, or wheelchairs) as needed. Botulinum toxin injections may be used for focal spasticity. Regular follow-up with a neurologist and rehabilitation specialist is recommended to monitor disease progression and adjust treatment accordingly.

Common questions about Autosomal dominant spastic paraplegia type 6